View Older Stories View More Recent Stories

May 17, 2021 07:00AM G1 Therapeutics Presents Two Posters at ISPOR Describing the Estimated Economic Impact of Treating Myelosuppression Among Patients with Extensive-Stage Small Cell Lung Cancer
May 10, 2021 06:50AM G1 Therapeutics Initiates Randomized Double Blind Placebo Controlled Phase 2 Study of COSELA™ (trilaciclib) in Non-Small Cell Lung Cancer (PRESERVE 4)
May 7, 2021 04:01PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 5, 2021 04:01PM G1 Therapeutics Provides First Quarter 2021 Financial Results and Operational Highlights
Apr 28, 2021 10:00AM G1 Therapeutics to Provide First Quarter 2021 Financial Results and Business Update on May 5, 2021
Apr 28, 2021 07:49AM G1 Therapeutics (GTHX) Begins Phase 3 Registrational Study of COSELA (trilaciclib) in Triple-Negative Breast Cancer
Apr 28, 2021 07:00AM G1 Therapeutics Announces Initiation of Phase 3 Registrational Study of COSELA™ (trilaciclib) in Triple-Negative Breast Cancer (TNBC)
Apr 26, 2021 09:44AM G1 Therapeutics (GTHX) Announces Publication of Pooled Results from Pivotal Clinical Program of COSELA™ (trilaciclib) in Clinical Lung Cancer
Apr 26, 2021 09:41AM G1 Therapeutics Announces Publication of Pooled Results from Pivotal Clinical Program of COSELA™ (trilaciclib) in Clinical Lung Cancer
Apr 7, 2021 07:00AM G1 Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
Apr 2, 2021 04:05PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 1, 2021 07:30AM G1 Therapeutics to Host Virtual COSELA™ (trilaciclib) Kickoff Analyst and Investor Summit on April 9, 2021
Mar 25, 2021 06:52AM G1 Therapeutics' (GTHX) COSELA Included in Two Updated National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology
Mar 25, 2021 06:50AM G1 Therapeutics’ COSELA™ (trilaciclib) Included in Two Updated National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology
Mar 5, 2021 04:05PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 3, 2021 07:30AM G1 Therapeutics to Participate in Two Investor Conferences in March
Mar 2, 2021 07:00AM G1 Therapeutics (GTHX) and Boehringer Ingelheim Announce Commercial Availability of COSELA
Mar 2, 2021 06:59AM G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib), the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemothera
Feb 24, 2021 04:01PM G1 Therapeutics Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
Feb 17, 2021 08:00AM G1 Therapeutics to Provide Fourth Quarter and Full Year 2020 Financial Results and Business Update on February 24, 2021
Feb 16, 2021 06:23AM G1 Therapeutics (GTHX) Announces FDA Approves its COSELA: The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
Feb 12, 2021 07:40PM FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
Feb 4, 2021 07:30AM G1 Therapeutics to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day Virtual Conference
Jan 5, 2021 07:00AM G1 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021
Jan 4, 2021 07:00AM G1 Therapeutics Announces Appointment of William C. Roberts as Vice President, Investor Relations & Corporate Communications
Jan 4, 2021 07:00AM G1 Therapeutics Announces Appointment of William C. Roberts as Vice President, Investor Relations & Corporate Communications
Dec 9, 2020 05:00PM G1 Therapeutics Presents Final Phase 2 Clinical Data on Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Surviv
Nov 24, 2020 07:00AM G1 Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020
Nov 18, 2020 07:00AM G1 Therapeutics to Present Clinical Data on Trilaciclib and Rintodestrant at 2020 San Antonio Breast Cancer Symposium (SABCS)
Nov 11, 2020 07:01AM G1 Therapeutics to Present at the Stifel Virtual Healthcare Conference on November 18, 2020
Nov 4, 2020 04:01PM G1 Therapeutics Provides Third Quarter 2020 Corporate and Financial Update
Oct 28, 2020 07:01AM G1 Therapeutics to Provide Third Quarter 2020 Corporate and Financial Update on November 4, 2020
Oct 15, 2020 07:00AM G1 Therapeutics to Present Data on Trilaciclib at North America Conference on Lung Cancer (NACLC)
Sep 30, 2020 04:02PM G1 Therapeutics (GTHX) announces John Bailey has been named as its next CEO
Sep 30, 2020 04:01PM G1 Therapeutics Announces Chief Executive Officer Succession Plan
Sep 14, 2020 07:00AM G1 Therapeutics to Present Data on Oral CDK4/6 Inhibitor Lerociclib at European Society for Medical Oncology (ESMO) Virtual 2020 Congress
Sep 2, 2020 07:01AM G1 Therapeutics to Participate in Four Investor Conferences in September 2020
Aug 17, 2020 06:04AM G1 Therapeutics (GTHX) Reports FDA Acceptance of NDA for Trilaciclib for Patients with SCLC
Aug 17, 2020 06:00AM G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung Cancer
Aug 17, 2020 06:00AM G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung Cancer
Aug 5, 2020 04:01PM G1 Therapeutics Provides Second Quarter 2020 Corporate and Financial Update
Aug 4, 2020 07:00AM G1 Therapeutics to Participate in BTIG and Wedbush Healthcare Conferences in August 2020
Aug 3, 2020 07:00AM G1 Therapeutics and Simcere Announce Exclusive License Agreement for Trilaciclib in Greater China
Jul 29, 2020 07:01AM G1 Therapeutics to Provide Second Quarter 2020 Corporate and Financial Update on August 5, 2020
Jul 22, 2020 06:00PM G1 Therapeutics Announces License Agreement for Lerociclib
Jun 30, 2020 04:10PM G1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib in Small Cell Lung Cancer in the United States and Puerto Rico
Jun 22, 2020 06:00AM G1 Therapeutics and Genor Biopharma Announce Exclusive License Agreement for Lerociclib in Asia-Pacific Region
Jun 1, 2020 04:01PM G1 Therapeutics Announces Flexible Credit Financing for Up to $100 Million with Hercules Capital
May 13, 2020 05:32PM G1 Therapeutics (GTHX) to Present Data Showing Myelopreservation Benefits of Trilaciclib in Patients with Small Cell Lung Cancer at the ASCO20 Virtual
May 13, 2020 05:31PM G1 Therapeutics to Present Data Showing Myelopreservation Benefits of Trilaciclib in Patients with Small Cell Lung Cancer at the ASCO20 Virtual Scientific Program
View More Recent Stories View Older Stories